Navigation Links
Sangamo BioSciences to Acquire Ceregene
Date:8/26/2013

expected to close in September 2013, subject to customary closing conditions.  The Company does not expect the acquisition, including the ongoing Phase 2 clinical trial, to have any impact on its financial guidance regarding 2013 operating expenses or yearend cash.  A more detailed description of the terms of the definitive agreement is available in the Form 8-K filed by the Company with the Securities and Exchange Commission on this date.

Sangamo will receive over 120 issued, pending or in-licensed patents that include patent families covering the AAV vector platform and manufacturing methods, therapeutic transgenes, and technology for direct administration of AAV to the brain.  Sangamo will also have access to GMP master cell banks, materials and manufacturing know-how that will expand its capabilities in AAV manufacturing as well as a database of preclinical efficacy and toxicology studies and other documentation supporting Ceregene's Investigational New Drug (IND) applications.  These materials provide valuable reference materials for Sangamo in the preparation and filing of IND applications for its in vivo ZFP Therapeutics®, particularly those that target the brain. In addition, Sangamo will acquire all of Ceregene's preclinical and clinical therapeutic programs including its ongoing double-blind, placebo-controlled Phase 2 trial to evaluate its NGF-AAV (CERE-110) in Alzheimer's disease (AD) and the proprietary needle device for brain delivery of AAV with supporting regulatory documentation and clinical experience.

In 2008, Ceregene, and its collaborators at the Alzheimer's Disease Cooperative Study (ADCS), based at the University of California, San Diego (UCSD), were awarded a $5.4 million grant from the National Institute of Aging of the National Institutes of Health (NIH) to support the double-blind, placebo-controlled, Phase 2 clinical trial of CERE-110 in 50 subjects with mild to moderate AD. Using
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
2. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
3. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
4. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
5. Sangamo BioSciences Reports First Quarter 2013 Financial Results
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
9. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
10. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
11. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 Research and Markets  has announced ... by Product, Component, Application and Geography - Global Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 ... witness a moderate growth as the markets of the ... reached the saturation levels. The demand is expected to ...
(Date:7/24/2014)... -- "North America Orthopedic Braces and Supports Market Outlook ... America Orthopedic Braces and Supports market. The report provides ... units) and average price data (in US dollars), within ... , Ankle Braces and Supports , Spinal ... Supports. Photo - http://photos.prnewswire.com/prnh/20140723/129806 ...
(Date:7/24/2014)...   Royal Philips (NYSE: PHG ... 510(k) clearance from the U.S. Food and Drug Administration ... in the U.S. VISIQ is the first ... mobility, performance and simplicity into a single miniaturized solution, ... more OB patients. This breakthrough ultrasound device ...
Breaking Medicine Technology:Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 2Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 3
... Inc. (NASDAQ: MSON ), a medical ... therapeutic ultrasonic products worldwide for wound debridement, spinal ... surgical and medical applications, has entered into a ... Instrument Co., Ltd., based in Taichung, Taiwan, R.O.C., ...
... 3, 2011 A new type of radiation therapy ... University Hospital that cuts down on treatment time while ... patient undergoes a lumpectomy to remove a cancerous tumor, ... can take an average of five weeks. But using ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Taiwan 2Misonix Announces New Distribution Agreement for Taiwan 3SIUH Offers New 5-Day Breast Cancer Therapy 2
(Date:7/24/2014)... -- A new formulation of a powerful narcotic painkiller ... drug has been approved by the U.S. Food and ... Purdue Pharma, the pill is a combination of the ... euphoric effects of oxycodone. The naloxone is only activated ... according to the FDA. While Targiniq has only ...
(Date:7/24/2014)... Annual National Venous Interventional Summit is available at: ... established Venous Endovascular Interventional Strategies group comprised of ... to provide a "How To" meeting for cardiologists ... advancing their knowledge and skills in venous interventions ... comprehensive venous interventional program. Topics at this year,s ...
(Date:7/24/2014)... ACRIA & AMIDA CARE TO COHOST WHITE HOUSE ONAP ... the Dates: August 7th & August 8th* , ... for Life” forums this August, led by Douglas Brooks, the ... AIDS Policy (ONAP). This will be a wonderful opportunity to ... organizations, consumers and advocates to advance the National HIV/AIDS Strategy ...
(Date:7/24/2014)... 24, 2014 National Analysts Worldwide, the ... it will operate globally under the name, NAXION ... woman-owned Employee Stock Ownership Plan (ESOP) organization led by ... Ph.D . The firm guides market strategy in ... , Said McDonald, “We wanted our name to ...
(Date:7/24/2014)... For the first time in her career, Susan ... singer first became a known musical commodity after appearing on the ... the show was “I Dreamed a Dream,” from Les Misérables and ... since her time on the reality show in 2009 and now ... American fans. The tour will kick off on October 8 at ...
Breaking Medicine News(10 mins):Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 3Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 2Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 4
... WASHINGTON, Sept. 18 Americans believe that,providing medical care ... top of our nation,s priorities, in line with resolving ... a new nationwide survey. What,s,more, three-quarters of the public ... military veterans., And what do Americans think should ...
... identified specific damages to the brain that may occur when ... study in mice found that those animals that lived alone ... more damage to neurons in one part of the brain ... studies in humans have shown that socially isolated heart attack ...
... primarily for blind people places a layer of information technology ... interest along their path as they pass them. , The ... of Michigan. Researchers will present their work at two conferences ... A to point B. They learn to count steps if ...
... is almost always adenocarcinoma or signet ring cell carcinoma ... cell carcinoma. We report a patient with adenocarcinoma of ... This is the first reported case of gastric cancer ... to be published on 28 May 2008 in the ...
... numerous randomized clinical trials (RCT) have evaluated, and ... treatment regimens. Surgery remains standard care for early ... have also shown a survival benefit associated with ... patterns of care for these cancers. A study ...
... Introduced, MINNEAPOLIS, Sept. 17 Today ClearWay ... Board Members and,thanked outgoing members for their service ... and Executive Director of the Honeywell,Foundation as well ... affairs for Honeywell, was elected as the new ...
Cached Medicine News:Health News:Survey Shows Most Americans Want Government to Stand Up for Veterans 2Health News:Survey Shows Most Americans Want Government to Stand Up for Veterans 3Health News:Study suggests why heart attack victims do better with social support 2Health News:Study suggests why heart attack victims do better with social support 3Health News:New Bluetooth system orients blind and sighted pedestrians 2Health News:New Bluetooth system orients blind and sighted pedestrians 3Health News:How to treat gastroesophageal adenocarcinom patients? 2Health News:ClearWay Minnesota(SM) Board Approves New Officers 2Health News:ClearWay Minnesota(SM) Board Approves New Officers 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: